Veronique Bouchet has over 25 years’ experience in the healthcare industry, and is the CMO of RowAnalytics, an AI enabled drug discovery and Precision Medicine company. Prior to this she was Founder Director of Novudel Associates, a lifesciences consulting and coaching company. Until 2011 she was Director of Corporate Strategy and Head of VC Relations at AstraZeneca, where she was responsible for delivering new strategic initiatives and ventures, as well as supporting the business development activities of the Innovative Medicine Units. Prior to this post, Veronique was Head of Venture Strategy with overal lresponsibility for AstraZeneca's global corporate venturing activities, and led the creation and $40m financing of the company's first spinout,Albireo. In addition Veronique has held a variety of international roles in the healthcare industry across several therapeutic areas and functions, including drug development, product strategy, medical marketing, business development, and mergers and acquisitions, at AstraZeneca in the UK and Gruenenthal GmbH in Germany. She has also worked in venture capital, as an investment manager with the Rothschild Bioscience Unit in London.
Veronique currently serves as the Senior Independent Director of International Biotechnology Trust plc., an investment trust listed on the London Stock Exchange. She is a member of the Council and Finance and Investment Committee of Queen Mary, University of London and serves on the Scientific Committee of Breast Cancer Now.
She has an MB BS from St Bartholomew’s Hospital Medical School, holds a BSc in Psychology from University College London and an MBA from INSEAD. Veronique has a Diploma (Distinction) from the Coaching Academy UK, and has been awarded the Institute of Directors’ Diploma in Company Direction (Distinction).